Zealiyas K, Teshome S, Feleke Haile A, Weigel C, Alemu A, Amogne W
Front Microbiol. 2023; 14:1270824.
PMID: 38029140
PMC: 10644458.
DOI: 10.3389/fmicb.2023.1270824.
Singh D, Nelson S, Pawelski A, Cantres-Velez J, Kansra A, Pauly N
PLoS Pathog. 2022; 18(10):e1010868.
PMID: 36190982
PMC: 9529132.
DOI: 10.1371/journal.ppat.1010868.
Bristol J, Brand J, Ohashi M, Eichelberg M, Casco A, Nelson S
PLoS Pathog. 2022; 18(4):e1010453.
PMID: 35472072
PMC: 9041801.
DOI: 10.1371/journal.ppat.1010453.
Gam Ze Letova C, Kalt I, Shamay M, Sarid R
Int J Mol Sci. 2021; 22(21).
PMID: 34769420
PMC: 8584431.
DOI: 10.3390/ijms222111994.
Wong Y, Meehan M, Burrows S, Doolan D, Miles J
J Cancer Res Clin Oncol. 2021; 148(1):31-46.
PMID: 34705104
PMC: 8752571.
DOI: 10.1007/s00432-021-03824-y.
B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
Romero-Masters J, Huebner S, Ohashi M, Bristol J, Benner B, Barlow E
PLoS Pathog. 2020; 16(2):e1008365.
PMID: 32059024
PMC: 7046292.
DOI: 10.1371/journal.ppat.1008365.
EBV and HHV-6 Circulating Subtypes in People Living with HIV in Burkina Faso, Impact on CD4 T cell count and HIV Viral Load.
Traore L, Nikiema O, Ouattara A, Compaore T, Soubeiga S, Diarra B
Mediterr J Hematol Infect Dis. 2017; 9(1):e2017049.
PMID: 28894558
PMC: 5584768.
DOI: 10.4084/MJHID.2017.049.
Persistent infection drives the development of CD8+ T cells specific for late lytic infection antigens in lymphocryptovirus-infected macaques and Epstein-Barr virus-infected humans.
Orlova N, Wang F, Fogg M
J Virol. 2011; 85(23):12821-4.
PMID: 21917961
PMC: 3209403.
DOI: 10.1128/JVI.05742-11.
Cervical cancer with human papilloma virus and Epstein Barr virus positive.
Prayitno A
J Carcinog. 2006; 5:13.
PMID: 16686948
PMC: 1550390.
DOI: 10.1186/1477-3163-5-13.
Multiple Epstein-Barr virus infections in healthy individuals.
Walling D, Brown A, Etienne W, Keitel W, Ling P
J Virol. 2003; 77(11):6546-50.
PMID: 12743312
PMC: 155020.
DOI: 10.1128/jvi.77.11.6546-6550.2003.
Identification of Epstein-Barr virus strain variants in hairy leukoplakia and peripheral blood by use of a heteroduplex tracking assay.
Sitki-Green D, Edwards R, Webster-Cyriaque J, Raab-Traub N
J Virol. 2002; 76(19):9645-56.
PMID: 12208943
PMC: 136523.
DOI: 10.1128/jvi.76.19.9645-9656.2002.
Epstein-Barr virus (EBV) subtype in EBV related oral squamous cell carcinoma in Okinawa, a subtropical island in southern Japan, compared with Kitakyushu and Kumamoto in mainland Japan.
Higa M, Kinjo T, Kamiyama K, Iwamasa T, Hamada T, Iyama K
J Clin Pathol. 2002; 55(6):414-23.
PMID: 12037022
PMC: 1769665.
DOI: 10.1136/jcp.55.6.414.
The immunology of Epstein-Barr virus infection.
Moss D, Burrows S, Silins S, Misko I, Khanna R
Philos Trans R Soc Lond B Biol Sci. 2001; 356(1408):475-88.
PMID: 11313006
PMC: 1088439.
DOI: 10.1098/rstb.2000.0784.
Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains.
Brooks J, Leese A, Tierney R, Habeshaw G, Rickinson A
J Virol. 2000; 74(4):1801-9.
PMID: 10644353
PMC: 111658.
DOI: 10.1128/jvi.74.4.1801-1809.2000.
Novel intertypic recombinants of epstein-barr virus in the chinese population.
Midgley R, Blake N, Yao Q, Croom-Carter D, Cheung S, Leung S
J Virol. 2000; 74(3):1544-8.
PMID: 10627567
PMC: 111491.
DOI: 10.1128/jvi.74.3.1544-1548.2000.
Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.
Aguirre A, Robertson E
J Virol. 2000; 74(2):735-43.
PMID: 10623735
PMC: 111593.
DOI: 10.1128/jvi.74.2.735-743.2000.
Evolution of two types of rhesus lymphocryptovirus similar to type 1 and type 2 Epstein-Barr virus.
Cho Y, Gordadze A, Ling P, Wang F
J Virol. 1999; 73(11):9206-12.
PMID: 10516028
PMC: 112954.
DOI: 10.1128/JVI.73.11.9206-9212.1999.
The molecular genetics of post-transplantation lymphoproliferative disorders.
Knowles D
Springer Semin Immunopathol. 1998; 20(3-4):357-73.
PMID: 9870251
DOI: 10.1007/BF00838049.
Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort.
Yao Q, Tierney R, Habeshaw G, Wilde J, Hill F, Conlon C
J Virol. 1998; 72(5):4352-63.
PMID: 9557725
PMC: 109665.
DOI: 10.1128/JVI.72.5.4352-4363.1998.
Apoptosis, proliferative activity and Bcl-2 expression in Epstein-Barr-virus-positive non-Hodgkin's lymphomas.
Takano Y, Saegusa M, Masuda M, Mikami T, Okayasu I
J Cancer Res Clin Oncol. 1997; 123(7):395-401.
PMID: 9260592
DOI: 10.1007/BF01240123.